Kornimate/medical-research-clean huggingface dataset:
intubating laryngeal mask vs direct laryngoscopy: a crossover randomized controlled preterm manikin trial

Conditions: Neonatal Disease; Intubation; Difficult or Failed

Summary: the study aims to compare the success and time of intubation through an intubating laryngeal mask vs. direct laryngoscopy in a manikin simulating a term infant. in addition, we will assess the operator's opinion on the procedure. this is an unblinded, randomized, controlled, crossover (ab/ba) pilot trial of intubation procedure through intubating laryngeal mask vs direct laryngoscopy in a manikin simulating a term newborn.

background: endotracheal intubation is an important life-saving procedure for critically ill neonates. furthermore, the procedure times are often longer than recommended by international guidelines, and repeated intubation attempts are associated with adverse events in unstable neonates. objectives: to compare success and time of intubation through intubating laryngeal mask vs. direct laryngoscopy in a manikin simulating a term infant. in addition, we will assess the operator's opinion on the procedure. methods: this is an unblinded, randomized, controlled, crossover (ab/ba) pilot trial of intubation procedure through intubating laryngeal mask vs direct laryngoscopy in a manikin simulating a term newborn. participants will be level iii nicu consultants and residents. randomization will be performed using a computer-generated random assignment list. the primary outcome measure was the intubation success rate at the first attempt. secondary outcome measures were the total time needed for the endotracheal tube positioning (calculated as the sum of the time of device positioning in all attempts), and the participant's opinion on using the device (evaluated using a likert scale).

Eligibility criteria:
inclusion criteria: * level iii nicu consultants and residents will be eligible to participate in the study exclusion criteria: * none
role of ultrasound elastography in differentiation of peripheral lung lesions

Conditions: Lung Diseases

Summary: advancements in imaging capacities and the development of a precise puncture-guiding transducer have made transthoracic ultrasonography a useful diagnostic tool for evaluating peripheral subpleural lung tumours. different human tissues have varying levels of elasticity because of the properties of the extracellular matrix. pleural two-dimensional (2d) shear-wave elastography (swe) can be used to differentiate between malignant pleural effusion and benign pleural disease. transthoracic 2d-swe uses acoustic radiation force and assesses the velocity of tissue displacement propagation in multiple focal zones. the shear waves are monitored in 2d by creating a near-cylindrical shear-wave cone, enabling measurement of the shear-wave speed or young's modulus (e) on a colour quantitative elastogram. based on the hypothesis that transthoracic 2d-swe could add accurate tissue stiffness information to b-mode grayscale ultrasound images and help in differentiating lung malignancy from benign lung lesions.

b-mode grayscale images will be used by ultrasound to assess peripheral lung lesions. information including size, location, and intercostal chest wall thickness will be collected. then, investigators will use transthoracic 2d-swe to assess those lesions. investigators intend to use regions of interest (rois) with 3-mm diameter, and select up to four rois with the highest mean elasticity values. the average as the final value will be calculated. if patients had multiple sub-pleural lung lesions, the largest and the most approachable one will be chosen to perform 2d-swe. final diagnosis will be made via appropriate diagnostic modalities including computed tomography of chest, microbiological results and guided biopsies if indicated.

Eligibility criteria:
inclusion criteria: * radiographic evidence of pulmonary lesions exclusion criteria: * patients less than 18 years. * patients refusing to participate in the study. * inability to hold breath for at least 5 s.

Keywords: ultrasound elastography lung lesions
does whole blood adsorber during cpb reduce vasoactive drugs postoperatively in endocarditis patients undergoing valve surgery?

Conditions: Infective Endocarditis

Summary: the study aims to investigate the effect of addition of an adsorber during cardio pulmonary bypassin patients with infective endocarditis undergoing valve surgery, and if it will decrease the use of vasoactive drugs postoperatively.


Eligibility criteria:
inclusion criteria: 1. infected endocarditis patients undergoing heart valve surgery. 2. age over 18 years. exclusion criteria: 1 declines participation
liver ischemia-reperfusion injury and clinical data analysis

Conditions: Liver Injury

Summary: searching for new targets for the diagnosis and treatment of liver ischemia-reperfusion injury.

through the analysis of serological data during liver resection elective surgery with hepatic pedicle occlusion and reperfusion, as well as the analysis of patient-related data, we aim to identify key target points that affect reperfusion injury and explore their underlying mechanisms.

Eligibility criteria:
inclusion criteria: 1. willingness to participate in the study and has signed an informed consent form. 2) age ≥ 18 years and ≤ 70 years. 3) asa classification ≤ iii. 4) criteria for liver ischemia-reperfusion injury patients: patients undergoing elective liver resection surgery with hepatic pedicle occlusion and reperfusion during the procedure. exclusion criteria: 1) patients with adverse events during surgery. 2) patients in the end stage of disease with liver failure. 3) liver tumor metastasis with concomitant severe heart failure or chronic renal insufficiency, etc. 4) deemed unsuitable for participation in the study based on the judgment of the researchers. -

Keywords: hepatic ischemia; reperfusion injury
a single-session intervention adaptation of the habit framework for the prevention of eating disorders

Conditions: Eating Disorder Not Otherwise Specified

Summary: the purpose of this proposal is to launch the first trial of a single-session intervention (ssi) specifically for the prevention of eating disorders (eds).

the emergence of eds is bimodal such that there is a period of risk in early adolescence and a period of risk in late adolescence/early adulthood. eds can lead to significant mental and physical health consequences and have one of the highest mortality rates of any mental illness. prevention and treatment programs for eds are fraught with barriers to access, particularly related to seeking care in-person. ssis have been identified as a pathway to address the gap in care for eds after showing promise for other psychiatric problems, including depression, anxiety, and suicidality .

Eligibility criteria:
inclusion criteria: * eat-26 score ≥ 20 ( eat-26, participants will meet the "referral criteria" which includes a score of 20 or more or meeting frequency criteria on bingeing, purging, laxative/diuretic use, and/or exercise.) * english-language fluency, self-reported3 * access to a phone, tablet, or computer exclusion criteria: * failure to correctly complete one of the attention checks in the survey prior to the intervention * failure to correctly complete both anagram tasks in the survey prior to the intervention * completion of the screening survey or pre-intervention surveys in an improbably fast time

Keywords: prevention of eating disorders
cancer-associated cachexia in patients with incurable gastroesophageal cancer

Conditions: Gastro-Esophageal Cancer

Summary: patients with incurable gastroesophageal cancer are at high risk of cancer cachexia with an estimated prevalence of 60-80%. cancer cachexia is defined as ongoing loss of skeletal muscle mass with or without loss of fat mass and is associated with impaired quality of life, loss of physical function, treatment intolerability, and increased mortality. cancer cachexia is a multifactorial syndrome, and in patients with gastroesophageal cancer, the wasting is compounded by a high prevalence of dysphagia. to date, no drug therapy has been approved for the treatment for cancer cachexia. sufficient nutritional support is imperative in cachexia treatment, but to effectively treat cancer cachexia there is a need to fully understand the biological mechanisms underpinning the wasting syndrome. the primary objective of the present cohort study is to determine the incidence and extend of skeletal muscle wasting in patients with incurable gastroesophageal cancer. the investigators will also investigate the prevalence of low skeletal muscle at time of diagnosis. the secondary objective is to investigate, if loss of skeletal muscle is associated with treatment intolerance and increased mortality. furthermore, the investigators aim to explore factors differentially expressed in the circulation, in skeletal muscle, and in adipose tissue of patients experiencing wasting compared with patients not experiencing wasting. the study is a prospective cohort study including patients with incurable gastroesophageal cancer referred to first line chemotherapy. blood and plasma samples as well as clinical and simple functional assessments will be obtained from all patients. the participants will also be offered to take part in a sub-study in which, we will collect skeletal muscle and subcutaneous adipose tissue. the main questions the investigators aim to answer are: * what is the prevalence and extent of skeletal muscle mass wasting in patients with incurable gastroesophageal cancer? * are the loss of skeletal muscle mass and low skeletal muscle mass associated with treatment intolerability and overall survival in patients with incurable gastroesophageal cancer? * can there be identified potential biological processes and factors in skeletal muscle, adipose tissue, and plasma that contribute to the loss of skeletal muscle mass in patients with incurable gastroesophageal cancer?


Eligibility criteria:
inclusion criteria: * patients eligible for participation are any patient diagnosed with histologically verified, incurable cancer of the esophagus, stomach, or gastroesophageal junction, referred to first line chemotherapy. exclusion criteria: * age \< 18 years

Keywords: cancer cancer cachexia sarcopenia neoplasms metabolism
assessing the role of inclined positioning in acute respiratory distress syndrome patients recovery

Conditions: ARDS, Human

Summary: the purpose of this study is to determine the effect of intermittent, nearly vertical, patient positioning in a specialized upright bed, on outcomes of mechanically ventilated patients with acute respiratory distress syndrome (ards) who are in the icu.

the purpose of this study is to determine the effect of intermittent, nearly vertical, patient positioning in a specialized upright bed, on outcomes of mechanically ventilated patients with acute respiratory distress syndrome (ards) who are in the icu. this study is a prospective, non-blinded, feasibility, randomized study of ards patients, who will be randomized into two treatment groups. one treatment arm will deliver scheduled sessions of upright bed positioning (study intervention), while the other treatment arm receives routine bed position care (care provided exclusively with the bed in the supine position). icu practitioners know that positional changes improve clinical outcomes when turning patients from supine to prone (back to belly); however, other positional changes including upright positioning are far less studied. it is well known that in ards patients who become proned, an improvement in aeration occurs in the dorsal lung regions (prone positioning has been shown to reduce ards mortality). thus the investigators predict that in this study, the upright positioning holds the potential to further recruit collapsed lung areas. augmentation of aerated lung while in the upright position is expected to increase the highest value measured per ventilator day of the respiratory system compliance in the upright bed position arm, in a greater fashion than the highest value measured per ventilator day of daily total respiratory system compliance for the usual care arm.

Eligibility criteria:
inclusion criteria: * berlin criteria ards exclusion criteria: * ards greater than 72 hours * neurologic disease known to prolong weaning * pregnancy * known diagnosis of pulmonary fibrosis * implanted cardiac pacer/defibrillator * prisoner
application of intra-operative prophylactic antibiotics/antiseptics in chinese breast reconstruction patients

Conditions: Breast Neoplasms

Summary: the study aims to investigate different approaches of local application of antibiotics/antiseptics intraoperatively in chinese patients undergoing post-mastectomy implant based breast reconstruction, and aims to single out an intervention method that limits the use of antibiotics and maintains low rates of surgical site infection and capsular contracture. patients who undergo post mastectomy breast reconstruction in the breast reconstruction department in tianjin medical university cancer institute and hospital are eligible to enter the study.

there is an ongoing trend towards implant based breast reconstruction in post-mastectomy patients in china. in 2015, more than 60% of patients undergoing breast reconstruction in tianjin medical university cancer institute and hospital opted for implant based breast reconstruction. one of the major complications in implant based breast reconstruction is infection, which could cause implant explantation, delay the time to adjuvant therapies in breast cancer patients, and inflict adverse psychological effects. although empirical intravenous and/or oral antibiotics are suggested peri-operatively, local applications of antibiotics/antiseptics and their combinations are applied differently in many medical centers worldwide, and some even suggest against the use of intraoperative local antibiotics. furthermore, there is no consensus as to the local application of antibiotics intraoperatively for breast reconstruction patients in chinese population. we therefore designed an open-label prospective randomized control trial in our chinese patient population to investigate the effects of three different approaches of intraoperative surgical site intervention with antibiotics and or antiseptics. in each groups, all peri-operative interventions are standardized to best reduce bias. short-term infection rate and long-term capsular contracture rate will be observed in the hope of singling out the best modality in our medical center to integrate into the overall comprehensive treatment for female breast cancer patients.

Eligibility criteria:
inclusion criteria: * patients who underwent mastectomy and eligible for implant-based breast reconstructions * karnofsky performance status (kps) larger than 70 * no severe deficiency in hematological, cardiovascular system, no immunodeficiency, no severe abnormal liver or kidney function exclusion criteria: * metastatic breast cancer * local or systemic infection within 30 days prior to breast reconstruction surgery * local, oral or systemic administration of any form of antibiotics within 30 days prior to breast reconstruction surgery * pre-operative complete blood count shows white blood cell (wbc) count \>10\*10\^9/l, neutrophil cell (n) count \> 7.5\*10\^9/l or n%\>80% * pre-operative blood procalcitonin (pct) higher than upper limit of the normal range * past history with injection breast augmentation

Keywords: implant-based breast reconstruction intraoperative antibiotics/antiseptics chinese
study of seraprevir in combination with sofosbuvir in chronic genotype 1 hepatitis c virus infection patients

Conditions: Hepatitis C Virus Infection

Summary: this study was to assess the safety and efficacy of seraprevir in combination with sofosbuvir administered for 12 weeks in patients with hepatitis c (hcv) genotype1. efficacy was assessed by the rate of sustained viral response (svr) 12 weeks after the discontinuation of therapy (svr12).


Eligibility criteria:
inclusion criteria: * hepatitis c virus (hcv) genotype 1 infection (confirmed at screening). * hcvrna greater than 10,000 iu/ml at screening. * participant must be willing and able to comply with the protocol requirements. * weight was more than 40 kg. * age is between 18-75,either sex. exclusion criteria: * co-infection with hepatitis b virus or human immunodeficiency virus (hiv). * infection with hcv non-genotype 1,or infection with mixed genotype,or genotype cannot be confirmed. * medical history of major functional organ transplantation. * suffering from serious blood system disease(such us thalassemia/sickle cell anemia). * participation in a clinical study within 3 months prior to first dose
to evaluate the preliminary safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of cc-11050 in subjects with discoid lupus erythematosus and subacute cutaneous lupus erythematosus

Conditions: Cutaneous Lupus Erythematosus

Summary: this is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of cc-11050.


Eligibility criteria:
key inclusion criteria: * subjects with a clinical diagnosis of discoid lupus erythematosus or sub acute lupus erythematosus for \> 16 weeks prior to screening and consistent histological findings on skin biopsy based on gilliam classification who are candidates for systemic therapies (as determined by the investigator) * must, in the opinion of the investigator, have active skin lesions of sufficient severity at screening and baseline (a cutaneous lupus area and severity index activity score of ≥ 10) * all subjects taking hydroxychloroquine, chloroquine or quinacrine during the study must have documentation of an ophthalmologic exam performed within 24 weeks of the baseline visit. * must meet the following laboratory criteria: * white blood cell count ≥3000/mm3 (≥ 3.0 x 109/l) and \< 14,000/mm3 (\< 14 x 109/l) * absolute neutrophil count (anc) \> 1500 cells/μl (1.5 x 109/l) * platelet count ≥ 100,000/μl (≥ 100 x 109/l) * serum creatinine ≤ 1.5 mg/dl (≤ 132.6 μmol/l) * aspartate aminotransferase (ast/sgot) and alanine aminotransferase (alt/sgpt) * ≤ 1.5 x upper limit of normal (uln) * total bilirubin \< 2mg/dl * hemoglobin \> 11 g/dl key exclusion criteria * participation in multiple cc-11050 cohorts or previous exposure to cc-11050 * presence or history of sle based on investigators' clinical evaluation where subject exhibits medically significant (as determined by the investigator) le-related pleuritis, pericarditis, neurologic, renal and/or other major sle-related organ system involvement(sle-related to sle joint involvement is acceptable). * use of topical or any local therapy known to possibly benefit discoid lupus erythematosus or scle sub acute lupus erythematosus within 2 weeks of the screening visit * use of concomitant disease modifying anti-rheumatic drugs (dmards) with the exception of anti-malarials within 4 weeks of screening- use of topical or any local therapy known to possibly benefit discoid lupus erythematosus or scle sub acute lupus erythematosus within 2 weeks of the screening visit * use of immunosuppressives (eg, azathioprine, mycophenolate mofetil, methotrexate, etc.) within 4 weeks of screening

Keywords: cutaneous lupus erythematosus subacute lupus erythematosus discoid lupus erythematosus lupus
clinical study of autologous erythrocytes derived mps packaging mtx peritoneal perfusion to treat malignant ascites

Conditions: Malignant Ascites

Summary: this study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant ascites. all the participants will randomly receive the treatment of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination or convention drugs peritoneal perfusion and systemic therapy combination.

as a drug carrier, erythrocytes have their own advantages, such as high biocompatibility, high immune compatibility, simple structure and easy access. in this study, microparticles released from erythrocytes are used as the carrier of chemotherapy drugs and effectively kill tumor cells in malignant ascites. these microparticles can easily reach the tumor site and bring the drug into tumor cells, which can overcome the two main problems in normal chemotherapy: damage to normal cells and drug resistance of tumor cells.

Eligibility criteria:
inclusion criteria: * 18 and ≤ 80 years of age * histological confirmed gastric cancer, colorectal cancer, or ovarian cancer, tumor cells were detected by exfoliative cytology of peritoneal effusion, refractory or recurrent ascites of ovarian cancer were required, other kinds of cancer were not limited * vital signs were stable, karnofsky ≥ 70, life expectancy of more than 3 months * the hematopoietic function of bone marrow was normal without bleeding tendency (inr \ 4.0 × 10\^9/l (neu ≥ 1.5 × 10\^9/l), plt ≥ 80 × 10\^9/l * liver function: stb ≤ 1.5 uln, ast and alt≤ 2.5 uln (if the abnormity of liver function was mainly caused by tumor invasion, ast and alt ≤ 5 uln), alp ≤ 1.5 uln * renal function: bun and cr ≤ 1.5 uln, ccr ≥ 50ml/min * ecg and blood glucose level were normal * patients or family members agreed to participate in the study and signed informed consent * no other serious heart and lung disease, etc. exclusion criteria: * pregnant or lactating women * allergic constitution and multi-drug allergy * serious heart, lung, liver and kidney dysfunction, decompensated heart, lung, kidney, liver and other major organs dysfunction or failure, poor blood glucose control, chemotherapy intolerance, combined intestinal obstruction * concurrent severe infection * hiv positive, hbsag and hbv dna copy number positive (quantitative detection ≥ 1000 cps/ml), chronic hepatitis c blood screening positive (hcv antibody positive) * cognitive impairment or poor chemotherapy compliance determined by investigator * less than 4 weeks from the last clinical trial * unsuitable for clinical trials determined by investigator

Keywords: microparticles erythrocytes methotrexate
additive anti-inflammatory action for aortopathy & arteriopathy (multicenter cohort study) iii

Conditions: Aortic Dissection

Summary: anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. the authors evaluated the inflammatory response in patients with aortic dissection (ad) and assessed the presence of distinct inflammatory subphenotypes within this disease.


Eligibility criteria:
inclusion criteria: * acute type aortic dissection; exclusion criteria: * iatrogenic aortic dissection or traumatic aortic dissection * patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases. * preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.

Keywords: aortic dissection inflammatory response